Melatonin's Biphasic Apoptotic Pathway in Breast Cancer Cells
Researchers in Rome, Italy, have made a significant breakthrough in understanding the effects of melatonin on breast cancer cells. Their study, published in the Journal of Pineal Research, reveals that melatonin triggers a unique biphasic apoptotic pathway in MCF-7 breast cancer cells, leading to cell death. The researchers discovered that melatonin exerts a significant growth-inhibitory effect on these cells, becoming evident after 72 hours and increasing linearly up to 144 hours.
Key Takeaways:
- Melatonin exerts a significant growth-inhibitory effect on MCF-7 breast cancer cells, with a 72-hour latency period and a linear increase up to 144 hours.
- The growth inhibition is transforming growth factor beta 1 (TGFbeta1)-dependent and can be reversed by adding an anti-TGFbeta1 antibody.
- Melatonin induces a significant rise in apoptotic rate at both 24 and 96 hours, with a biphasic apoptotic pathway consisting of an early, TGFbeta1 and caspase-independent response, and a late apoptotic TGFbeta1-dependent process.
- The early programmed cell death is associated with a significant increase in the p53/MDM2 ratio and in AIF release, without modifications in caspase activity or cleaved-PARP levels.
- Activated caspases-9 and -7 and cleaved-PARP increase significantly at 96 hours, concomitantly with a down-regulation of the Bcl-2/Bax ratio.
Statistics:
- 72 hours: latency period for melatonin's growth-inhibitory effect on MCF-7 cells
- 144 hours: maximum growth inhibition observed
- 24 hours: significant rise in apoptotic rate after melatonin treatment
- 96 hours: significant rise in activating caspases-9 and -7 and cleaved-PARP, with a down-regulation of the Bcl-2/Bax ratio
Sources:
- A. Cucina et al. "Evidence for a biphasic apoptotic pathway induced by melatonin in MCF-7 breast cancer cells." Journal of Pineal Research, 2009; 46(2): 172-80.
- Breast Cancer Cell Biology
- Blackwell Publishing Inc. Journal of Pineal Research 2009; 46(2)
- NewsRx.com